A recent study suggests that “among women living at least 1 year after a breast cancer diagnosis, aspirin use [is] associated with a decreased risk of distant recurrence and breast cancer death.”

This is a plausible premise since another recent study found that in “postmenopausal women, regular users of aspirin and other analgesics may have lower estrogen levels than nonusers” and lower estrogen levels can theoretically decrease the risk of breast or ovarian cancers.

Although more studies are needed to assess aspirin’s mechanism of action in this context, it seems like a drug with the potential to significantly reduce breast cancer deaths can be readily found at the local pharmacy.

Filed under: Science and Medicine